Document is current
Any future updates will be listed below
-
Authors
Stasik, Sebastian
Eckardt, Jan-Niklas
Röllig, Christoph
Baldus, Claudia D.
Serve, Hubert
Müller-Tidow, Carsten
Schäfer-Eckart, Kerstin
Kaufmann, Martin
Krause, Stefan W.
Hänel, Mathias
Neubauer, Andreas
Ehninger, Gerhard
Platzbecker, Uwe
Bornhäuser, Martin
Schetelig, Johannes
Middeke, Jan M.
Thiede, Christian
-
Funding
Funding for this research was provided by:
Technische Universität Dresden
- License Information
-
More Information
Article History
Received: 8 October 2025
Accepted: 6 December 2025
First Online: 22 January 2026
Declarations
:
: All samples were collected with written informed consent and after approval by the local ethics committee of the Medical Faculty Carl Gustav Carus Dresden, Germany. The study protocols were designed and applied in accordance with the principles of the Declaration of Helsinki.
: Not applicable.
: All patients were treated with intensive regimens in the following clinical trials: AML96 (NCT00180115), AML2003 (NCT00180102), AML60 + (NCT00180167), and SORAML (NCT00893373) or were enrolled in the German Study Alliance Leukemia (SAL)’s AML registry (NCT03188874).
: I confirm that no material requiring permission to reproduce from other sources has been included in the paper.
: CT is CEO and co-owner of AgenDix GmbH, a company performing molecular diagnostics. The remaining authors declare no conflict of interest.
